Cargando…

P1247: GB5121 IS A NOVEL, IRREVERSIBLE, COVALENT BTK INHIBITOR WITH HIGH SELECTIVITY AND CNS-PENETRANCE FOR TREATMENT OF CNS MALIGNANCIES

Detalles Bibliográficos
Autores principales:	Yusuf, I., Guimond, D., Naiman, Z., Schiff, T., Clemons, B., Paulson, B., Hou, K., Taylor Meadows, K., Rose, M., Carter, L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430246/ http://dx.doi.org/10.1097/01.HS9.0000847852.69497.6d

Ejemplares similares

PB2096: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT BTK INHIBITOR FOR RELAPSED/REFRACTORY PRIMARY/SECONDARY CNS LYMPHOMA AND PRIMARY VITREORETINAL LYMPHOMA
por: Soussain, C., et al.
Publicado: (2022)

CLRM-15 TRIAL IN PROGRESS: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT INHIBITOR OF BRUTON’S TYROSINE KINASE (BTKI) FOR RELAPSED/REFRACTORY PRIMARY/SECONDARY CNS LYMPHOMA (R/R PCNSL/SCNSL) AND PRIMARY VITREORETINAL LYMPHOMA (PVRL)
por: Soussain, Carole, et al.
Publicado: (2022)

Secondary CNS myeloma with remission after systemic CNS-penetrating agents
por: Fernandez, Luis G, et al.
Publicado: (2022)

CNS penetration of potential anti-COVID-19 drugs
por: Richardson, Peter J., et al.
Publicado: (2020)

Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors
por: Zain, Rula, et al.
Publicado: (2021)

Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals
por: Nwogu, Jacinta Nwamaka, et al.
Publicado: (2016)

Flavonoids and the CNS
por: Jäger, Anna K., et al.
Publicado: (2011)

CNS and CNS diseases in relation to their immune system
por: Xu, Jianhao, et al.
Publicado: (2022)

Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition
por: Jiménez, Isabel, et al.
Publicado: (2020)

1247. Going Viral with Antimicrobial Stewardship
por: Jenkins, Abi, et al.
Publicado: (2023)

Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
por: Bauer, Todd M., et al.
Publicado: (2020)

51.21 THE RELATIONSHIP BETWEEN COVID-19 LIFE DISRUPTIONS AND ANXIETY SEVERITY
por: Ruiz, Elaine, et al.
Publicado: (2020)

Comparison of inhibitory effects of irreversible and reversible Btk inhibitors on platelet function
por: Tullemans, Bibian M.E., et al.
Publicado: (2021)

CNS Tuberculosis
por: Sheller, James R., et al.
Publicado: (1986)

ML-10 Tirabrutinib, a second-generation BTK inhibitor in relapsed and refractory primary CNS lymphoma: A single institute study
por: Mishima, Kazuhiko, et al.
Publicado: (2021)

Incidence of childhood CNS tumours
por: Morland, B J, et al.
Publicado: (1999)

CNS Complications of Malignant Disease
por: Calman, K. C.
Publicado: (1980)

Transcriptional and epigenomic landscapes of CNS and non-CNS vascular endothelial cells
por: Sabbagh, Mark F, et al.
Publicado: (2018)

The Role of Peripheral CNS-Directed Antibodies in Promoting Inflammatory CNS Demyelination
por: Kinzel, Silke, et al.
Publicado: (2017)

Lead Optimization of Benzoxazolone Carboxamides as Orally Bioavailable and CNS Penetrant Acid Ceramidase Inhibitors
por: Di Martino, Simona, et al.
Publicado: (2020)

Glibenclamide for the Treatment of Acute CNS Injury
por: Kurland, David B., et al.
Publicado: (2013)

Discovery of a potent BTK and IKZF1/3 triple degrader through reversible covalent BTK PROTAC development
por: Yu, Xin, et al.
Publicado: (2022)

PB1912: BTK AND PLCG2 GENE MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH RESISTANCE TO COVALENT BTK INHIBITOR
por: Likold, Ekaterina, et al.
Publicado: (2023)

Agrin at CNS synapses
por: Dove, Alan W.
Publicado: (2003)

Pediatric CNS Tumors
por: Gaze, M
Publicado: (2004)

CNS Diseases and Uveitis
por: Allegri, Pia, et al.
Publicado: (2011)

Primary CNS Teratocarcinoma
por: Vitorovic, Danilo, et al.
Publicado: (2012)

Interleukin 18 in the CNS
por: Alboni, Silvia, et al.
Publicado: (2010)

Pediatric CNS tumors
por: Gupta, Nalin, et al.
Publicado: (2010)

Primary CNS Lymphoma
por: Phillips, Elizabeth H., et al.
Publicado: (2014)

The CNS and bladder dysfunction
por: Tadic, Stasa D., et al.
Publicado: (2012)

Trafficking of lymphocytes into the CNS
por: Schwab, Nicholas, et al.
Publicado: (2015)

CNS Malformations in the Newborn
por: Barañano, Kristin, et al.
Publicado: (2022)

Meningiomas with CNS invasion
por: Gousias, Konstantinos, et al.
Publicado: (2023)

Methods for culturing adult CNS neurons reveal a CNS conditioning effect
por: van Niekerk, Erna A., et al.
Publicado: (2022)

Molecular identification of CNS NB-FOXR2, CNS EFT-CIC, CNS HGNET-MN1 and CNS HGNET-BCOR pediatric brain tumors using tumor-specific signature genes
por: Łastowska, Maria, et al.
Publicado: (2020)

Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma
por: Wu, Hong, et al.
Publicado: (2014)

A covalent BTK ternary complex compatible with targeted protein degradation
por: Schiemer, James, et al.
Publicado: (2023)

Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model
por: Wu, Hong, et al.
Publicado: (2017)

Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery
por: Ghose, Arup K., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_3jfgh7h1eke1ju98ul1degmqpo